IP Library › Granted Patent US 12697373
Granted Patent B2
US 12697373 · App. 17/582,974 · Granted Aug 4, 2026

Blood plasma fractions as a treatment for aging-associated cognitive disorders

Inventors: David Bell (Dublin, IE); Ian Gallager (Half Moon Bay, CA); Steven P. Braithwaite (Redwood City, CA); S. Sakura Minami (San Francisco, CA); Vu Dang (San Mateo, CA); Joe McCracken (Hillsborough, CA); Karoly Nikolich (Emerald Hills, CA)
Assignee: Alkahest, Inc.
A61K38/385A61K35/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697373
App. No.
17/582,974
Granted
Aug 4, 2026
Kind
B2
Abstract

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Claims (18)

1 . A method of reducing a cognitive impairment in a subject having an aging-associated cognitive disorder, the method comprising administering to the subject an effective amount of a Plasma Fraction, wherein the Plasma Fraction consists of the soluble fraction Effluent II/III.

2 . The method of claim 1 , further comprising monitoring the subject for improved cognitive function.

3 . The method of claim 1 , wherein the Plasma Fraction is derived from plasma from a pool of young individuals.

4 . The method of claim 1 , wherein the Plasma Fraction is produced from a mammalian blood product.

5 . The method of claim 4 , wherein the mammalian blood product is a human blood product.

6 . The method of claim 1 , wherein the subject is a mammal.

7 . The method of claim 6 , wherein the mammal is a human.

8 . The method of claim 1 , wherein the aging-associate cognitive impairment is mild cognitive impairment.

9 . The method of claim 1 , wherein the aging-associate cognitive impairment is a Parkinson's Disease (PD)-associated cognitive impairment.

10 . The method of claim 9 , wherein in the PD-associated cognitive impairment is in an impairment in attention, concentration, working memory, executive function, producing language, or visuospatial function.

11 . The method of claim 1 , wherein the aging-associate cognitive impairment is dementia associated cognitive impairment.

12 . The method of claim 11 , wherein the dementia associated cognitive impairment is an impairment in language, memory, complex visual processing, or executive function.

13 . The method of claim 1 ,

wherein the administered Effluent II/III is prepared from plasma by the steps comprising:

i) using ethanol at the final concentration of 8% (v/v) to precipitate Fraction I,

ii) separating Effluent I from Fraction I,

iii) using ethanol at the final concentration of 21% (v/v) to precipitate Fraction II/III from Effluent I, and

iv) separating the soluble fraction Effluent II/III from the precipitated Fraction II/III.